000289463 001__ 289463
000289463 005__ 20241228120954.0
000289463 0247_ $$2doi$$a10.1016/j.esmoop.2024.102982
000289463 0247_ $$2pmid$$apmid:38613909
000289463 037__ $$aDKFZ-2024-00785
000289463 041__ $$aEnglish
000289463 082__ $$a610
000289463 1001_ $$0P:(DE-He78)35a941418cdcc6c595b7a8a19e355599$$aGwenzi, Tafirenyika$$b0$$eFirst author$$udkfz
000289463 245__ $$aPost-operative C-reactive protein as a strong independent predictor of long-term colorectal cancer outcomes: consistent findings from two large patient cohorts.
000289463 260__ $$aLondon$$bBMJ$$c2024
000289463 3367_ $$2DRIVER$$aarticle
000289463 3367_ $$2DataCite$$aOutput Types/Journal article
000289463 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1713266232_20788
000289463 3367_ $$2BibTeX$$aARTICLE
000289463 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289463 3367_ $$00$$2EndNote$$aJournal Article
000289463 500__ $$a#EA:C120#LA:C120#LA:C070#
000289463 520__ $$aPost-surgery blood-based biomarkers may be useful for guiding treatment and surveillance decisions among colorectal cancer (CRC) patients. However, most candidate biomarkers provide little if any predictive value beyond stage at diagnosis. We aimed to investigate the independent prognostic value of post-operative serum C-reactive protein (CRP), a highly sensitive biomarker of inflammation, for long-term CRC outcomes in two large patient cohorts.CRP levels were measured from serum samples of CRC patients collected ≥1 month post-surgery in the German DACHS (n = 1416) and the UK Biobank (n = 1149) cohorts. Associations of post-operative CRP with overall survival (OS) and CRC-specific survival (CSS) were assessed using Cox regression and presented as hazard ratios (HRs) with 95% confidence intervals (CIs), adjusted for key sociodemographic and clinical covariates.In both cohorts, consistent strong dose-response relationships between post-operative CRP and both OS and CSS were observed. Adjusted HRs (95% CI) for CRP >10 versus <3 mg/l were 1.93 (1.58-2.35) and 2.70 (2.03-3.59) in the DACHS cohort, and 2.70 (1.96-3.71) and 2.61 (1.83-3.72) in the UK Biobank cohort, respectively. Associations between post-operative CRP and OS were particularly strong among younger patients (<65 years at diagnosis; P value for interaction by age <0.01).Serum CRP determined a month or more after surgery may be useful as a strong independent prognostic biomarker for guiding therapeutic decisions and for surveillance of the course of disease of CRC patients, particularly those <65 years of age at diagnosis.
000289463 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000289463 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289463 650_7 $$2Other$$aC-reactive protein
000289463 650_7 $$2Other$$acolorectal
000289463 650_7 $$2Other$$aprognosis
000289463 650_7 $$2Other$$asurvival
000289463 650_7 $$2Other$$asystemic inflammation
000289463 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, P.$$b1$$udkfz
000289463 7001_ $$aAnker, S. C.$$b2
000289463 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, B.$$b3$$udkfz
000289463 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, M.$$b4$$udkfz
000289463 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$eLast author$$udkfz
000289463 773__ $$0PERI:(DE-600)2844985-X$$a10.1016/j.esmoop.2024.102982$$gVol. 9, no. 4, p. 102982 -$$n4$$p102982$$tESMO open$$v9$$x2059-7029$$y2024
000289463 8767_ $$8E-2024-00545-b$$92024-08-22$$d2024-12-27$$eHybrid-OA$$jZahlung erfolgt
000289463 909CO $$ooai:inrepo02.dkfz.de:289463$$pVDB$$pOpenAPC$$popenCost
000289463 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)35a941418cdcc6c595b7a8a19e355599$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000289463 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000289463 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000289463 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000289463 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000289463 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000289463 9141_ $$y2024
000289463 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bESMO OPEN : 2022$$d2023-10-27
000289463 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000289463 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000289463 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-27
000289463 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T14:49:18Z
000289463 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T14:49:18Z
000289463 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-04-12T14:49:18Z
000289463 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000289463 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-27
000289463 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000289463 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-27
000289463 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-27
000289463 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bESMO OPEN : 2022$$d2023-10-27
000289463 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-27
000289463 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-27
000289463 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000289463 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000289463 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000289463 915pc $$0PC:(DE-HGF)0125$$2APC$$aDEAL: Elsevier 09/01/2023
000289463 915pc $$0PC:(DE-HGF)0003$$2APC$$aDOAJ Journal
000289463 9202_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000289463 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000289463 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000289463 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000289463 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000289463 9200_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000289463 980__ $$ajournal
000289463 980__ $$aVDB
000289463 980__ $$aI:(DE-He78)C120-20160331
000289463 980__ $$aI:(DE-He78)C070-20160331
000289463 980__ $$aI:(DE-He78)HD01-20160331
000289463 980__ $$aUNRESTRICTED
000289463 980__ $$aAPC